Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06848387
PHASE4

Unbound Cloxacillin Concentrations During Continuous Infusion

Sponsor: Emeli Månsson

View on ClinicalTrials.gov

Summary

Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.

Official title: Concentration of Unbound Cloxacillin in Adults Treated With Continuous Infusion Via Elastomeric Pump

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

25

Start Date

2026-01-14

Completion Date

2027-12

Last Updated

2026-02-17

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

Unbound cloxacillin concentration

Unbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.

Locations (1)

Västmanlands sjukhus Västerås

Västerås, Sweden